Recent advances in nanomaterials for the treatment of spinal cord injury

Gong, Weiquan; Zhang, Tianhui; Che, Mingxue; Wang, Yongjie; He, Chuanyu; Liu, Lidi; Lv, Zhenshan; Xiao, Chunsheng; Wang, Hao; Zhang, Shaokun

doi:10.1016/j.mtbio.2022.100524

Cited by 9 publications

(7 citation statements)

References 175 publications

(243 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase I/II clinical trials using nanoparticle-drug conjugates targeting brain tumors through the blood-brain barrier (BBB) are underway, demonstrating the potential of nanoparticles in traversing barriers. Nanoparticles from biological (exosomes) and synthetic (lipids) sources have shown promise in improving motor functions and restoring tight junctions to attenuate BSCB leakage post SCI [96]. Various types of nanoparticles, including metals, polymers, and lipids, have been explored as tracers and drug delivery systems in SCI, showing significant reductions in inflammatory factors and enhancement of neuronal regeneration [97].…”

Section: Regulation Of Microglial Migration and Recruitmentmentioning

confidence: 99%

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

Schreiner,

Ciobanu

2024

JCM

View full text Add to dashboard Cite

Spinal cord injury is a complicated medical condition both from the clinician’s point of view in terms of management and from the patient’s perspective in terms of unsatisfactory recovery. Depending on the severity, this disorder can be devastating despite the rapid and appropriate use of modern imaging techniques and convenient surgical spinal cord decompression and stabilization. In this context, there is a mandatory need for novel adjunctive therapeutic approaches to classical treatments to improve rehabilitation chances and clinical outcomes. This review offers a new and original perspective on therapies targeting the microglia, one of the most relevant immune cells implicated in spinal cord disorders. The first part of the manuscript reviews the anatomical and pathophysiological importance of the blood-spinal cord barrier components, including the role of microglia in post-acute neuroinflammation. Subsequently, the authors present the emerging therapies based on microglia modulation, such as cytokines modulators, stem cell, microRNA, and nanoparticle-based treatments that could positively impact spinal cord injury management. Finally, future perspectives and challenges are also highlighted based on the ongoing clinical trials related to medications targeting microglia.

show abstract

Section: Regulation Of Microglial Migration and Recruitmentmentioning

confidence: 99%

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

Schreiner,

Ciobanu

2024

JCM

View full text Add to dashboard Cite

show abstract

“…The nanoparticle penetration of the blood-spinal cord barrier (B-SCB) and subsequent parenchymal accumulation is a complex interplay between NP size and delivery methodology, cargo, and /or the target cell/mechanism of interest [8][9][10]. Larger NPs, such as those sized 190 nm and 500 nm, have been shown to induce less cell membrane damage and limit infiltration of pro-inflammatory monocytes into the injury site, improving functional recovery in SCI rodents [11,12].…”

Section: Nanoparticle Sizementioning

confidence: 99%

The Translation of Nanomedicines in the Contexts of Spinal Cord Injury and Repair

Wang,

Yong,

Marciano

et al. 2024

Cells

View full text Add to dashboard Cite

Purpose of this review: Manipulating or re-engineering the damaged human spinal cord to achieve neuro-recovery is one of the foremost challenges of modern science. Addressing the restricted permission of neural cells and topographically organised neural tissue for self-renewal and spontaneous regeneration, respectively, is not straightforward, as exemplified by rare instances of translational success. This review assembles an understanding of advances in nanomedicine for spinal cord injury (SCI) and related clinical indications of relevance to attempts to design, engineer, and target nanotechnologies to multiple molecular networks. Recent findings: Recent research provides a new understanding of the health benefits and regulatory landscape of nanomedicines based on a background of advances in mRNA-based nanocarrier vaccines and quantum dot-based optical imaging. In relation to spinal cord pathology, the extant literature details promising advances in nanoneuropharmacology and regenerative medicine that inform the present understanding of the nanoparticle (NP) biocompatibility–neurotoxicity relationship. In this review, the conceptual bases of nanotechnology and nanomaterial chemistry covering organic and inorganic particles of sizes generally less than 100 nm in diameter will be addressed. Regarding the centrally active nanotechnologies selected for this review, attention is paid to NP physico-chemistry, functionalisation, delivery, biocompatibility, biodistribution, toxicology, and key molecular targets and biological effects intrinsic to and beyond the spinal cord parenchyma. Summary: The advance of nanotechnologies for the treatment of refractory spinal cord pathologies requires an in-depth understanding of neurobiological and topographical principles and a consideration of additional complexities involving the research’s translational and regulatory landscapes.

show abstract

“…[ 125 ] Efficient transport will significantly improve the bioavailability of drugs. [ 126 ] Endows NPs with one or more therapeutic functions, such as excellent antioxidant and anti‐inflammatory properties, immunomodulatory abilities, and promotion of axon growth, can lead to the development of SCI toward repair and regeneration. [ 126 ] Various NPs are manufactured based on biodegradable organic materials, inorganic non‐metallic materials, metal materials, etc.…”

Section: Nanoparticle‐based Multimodal Strategy For Treating Scimentioning

confidence: 99%

“…[ 126 ] Endows NPs with one or more therapeutic functions, such as excellent antioxidant and anti‐inflammatory properties, immunomodulatory abilities, and promotion of axon growth, can lead to the development of SCI toward repair and regeneration. [ 126 ] Various NPs are manufactured based on biodegradable organic materials, inorganic non‐metallic materials, metal materials, etc. The characteristics of these nanoparticle‐based drugs are discussed below, and the main information is summarized in Table 2 .…”

Section: Nanoparticle‐based Multimodal Strategy For Treating Scimentioning

confidence: 99%

Hydrogel and Nanomedicine‐Based Multimodal Therapeutic Strategies for Spinal Cord Injury

Yin,

Liang,

Han

et al. 2023

Small Methods

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a severe neurodegenerative disease caused by mechanical and biological factors, manifesting as a loss of motor and sensory functions. Inhibition of injury expansion and even reversal of injury in the acute damage stage of SCI are important strategies for treating this disease. Hydrogels and nanoparticle (NP)‐based drugs are the most effective, widely studied, and clinically valuable therapeutic strategies in the field of repair and regeneration. Hydrogels are 3D flow structures that fill the pathological gaps in SCI and provide a microenvironment similar to that of the spinal cord extracellular matrix for nerve cell regeneration. NP‐based drugs can easily penetrate the blood‐spinal cord barrier, target SCI lesions, and are noninvasive. Hydrogels and NPs as drug carriers can be loaded with various drugs and biological therapeutic factors for slow release in SCI lesions. They help drugs function more efficiently by exerting anti‐inflammatory, antioxidant, and nerve regeneration effects to promote the recovery of neurological function. In this review, the use of hydrogels and NPs as drug carriers and the role of both in the repair of SCI are discussed to provide a multimodal strategic reference for nerve repair and regeneration after SCI.

show abstract

Recent advances in nanomaterials for the treatment of spinal cord injury

Cited by 9 publications

References 175 publications

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

Spinal Cord Injury Management Based on Microglia-Targeting Therapies

The Translation of Nanomedicines in the Contexts of Spinal Cord Injury and Repair

Hydrogel and Nanomedicine‐Based Multimodal Therapeutic Strategies for Spinal Cord Injury

Contact Info

Product

Resources

About